(Q38212956)

31 August 2017

title

Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future (English)

1 reference

31 August 2017

1 reference

J M Jaso

1

1 reference

31 August 2017

S A Wang

series ordinal

2

1 reference

31 August 2017

J L Jorgensen

series ordinal

3

1 reference

31 August 2017

P Lin

series ordinal

4

1 reference

31 August 2017

language of work or name

English

0 references

publication date

19 May 2014

1 reference

Bone Marrow Transplantation

31 August 2017

published in

1 reference

31 August 2017

volume

49

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

1129-1138

1 reference

Acute myeloid leukemia: 2013 update on risk-stratification and management

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Relapsed acute myeloid leukemia: why is there no standard of care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

A novel hierarchical prognostic model of AML solely based on molecular mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Minimal residual disease in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Leukaemia antigens and immunity in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Specificity of heteroantisera to human acute leukemia-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Proceedings: Surface antigens of leukaemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Human hematopoietic lineage commitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Towards individualized follow-up in adult acute myeloid leukemia in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Should evaluation for minimal residual disease be routine in acute myeloid leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Assessment of minimal residual disease in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Development of minimal residual disease-directed therapy in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

A multidimensional classification approach for the automated analysis of flow cytometry data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Critical assessment of automated flow cytometry data analysis techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.99

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia

21 January 2018

1 reference

12 December 2020

Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia.

1 reference

12 December 2020

Characterization of aberrant phenotypes in acute myeloblastic leukemia

1 reference

12 December 2020

The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse

1 reference

12 December 2020

Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data

1 reference

12 December 2020

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

12 December 2020

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

1 reference

12 December 2020

Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients

1 reference

12 December 2020

Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis

1 reference

12 December 2020

Immunophenotypic analysis with enhanced sensitivity of detection by enzymatic amplification staining.

1 reference

12 December 2020

Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients

1 reference

12 December 2020

Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.

1 reference

12 December 2020

Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting

1 reference

12 December 2020

Expression of unusual immunophenotype combinations in acute myelogenous leukemia

1 reference

12 December 2020

Minimal residual disease in acute myeloid leukemia: coming of age.

1 reference

12 December 2020

The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse

1 reference

12 December 2020

Multicolor immunophenotyping: human immune system hematopoiesis

1 reference

12 December 2020

Identifiers

DOI

10.1038/BMT.2014.99

1 reference

Dimensions Publication ID

31 August 2017

1022937591

0 references

1 reference